OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024 London and New York, NY

Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024

and New York, NY, April 8, 2024 - OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical

company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market,

and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an

FDA approved therapy, announces that it will be rescheduling a Key Opinion Leader (KOL) event entitled "KOL Event Presenting

Comprehensive Detailed Results from the Phase 2 Trial of OK-101 in Dry Eye Disease" originally planned for April 9th, 2024 at 12:00

PM ET until May 2024. The Company is rescheduling its event so that it can incorporate additional key analyses of its clinical data which

it plans to present at upcoming ophthalmic conferences.

is planning to make a presentation at "Dry Horizons Symposium Navigating the Future of Dry Eye Research", an event preceding

the Association for Research in Vision and Ophthalmology (ARVO) conference with details provided below.

Friday May 3, 2024, 2:50-3:45 PM PST

Four Seasons Seattle, WA

Gary Jacob, PhD, Chief Executive Officer

Dry Horizons Symposium

clinical leaders and industry innovators to tackle significant challenges in the dry eye market. With the rising prevalence of dry eye

disease, the shortcomings of existing treatments, as well as new opportunities for advancing clinical pathways based on recent successful

therapies, this symposium will provide in-depth coverage of the global landscape of Dry Eye and the opportunity for further innovation.

From the impact of technology use on eye health, to unexplored therapeutics, to accelerating research and development, this new event

will showcase the urgent need for innovative clinical solutions to benefit current and future patients.

is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of

the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide technology to produce a novel

long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing efficacy

signals in mouse models of dry eye disease and corneal neuropathic pain (NCP), respectively, and is designed to combat washout through

the inclusion of the lipid anchor built into the drug molecule to enhance the residence time of OK-101 within the ocular environment.

OK-101 recently showed statistical significance in multiple endpoints in a recently completed Phase 2, multi-center, double-blind, placebo-controlled

trial of OK-101 to treat DED.

Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED

and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel

molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway

for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please

visit www.okyopharma.com.

statements made in this announcement are forward-looking statements, including with respect to the anticipated timing of completion of

enrolment of the Company's Phase 2 trial of topical ocular OK-101 to treat DED and the release of top-line data therefrom. These

forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and

projections about its industry, its beliefs, and assumptions. Words such as anticipates,' expects,' intends,'

plans,' believes,' seeks,' estimates,' and similar expressions are intended to identify

forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties,

and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to

differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective

security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the

date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the

statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking

statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required

by law or by any appropriate regulatory authority.